--- title: "Fen-Phen: The Weight Loss Drug that Destroys Your Heart" description: "In the spring of 1996, a woman in Virginia named Sabine Sisk-Bisson decided she wanted to lose about fifteen pounds. She had just quit smoking, and the weight had crept on the way it does after people put down cigarettes. Her doctor wrote her a prescription for a diet drug combination that was everywhere that year, advertised in magazines and stocked in clinics across the country.\n\nThe brand name on everyone's lips was Fen-Phen, and the early weeks did exactly what the marketing promised her. Her appetite quieted down, her clothes started fitting differently, and nothing about the routine felt reckless to anyone involved. It was legal, it was prescribed by a licensed physician, and she took it on the schedule she had been given.\n\nWhile the number on her scale was dropping, something else was happening inside her chest that no scale could measure. The valves of her heart were quietly thickening and beginning to leak, a process unfolding without symptoms she could feel. She didn't know yet, her doctor didn't know yet, and neither did the millions of other Americans swallowing the same combination that year.\n\nThe exhaustion came first, the kind that doesn't match the day you've had. A small hill left her winded, and long phone calls became difficult to get through without stopping to breathe. By the time her tests came back showing an enlarged heart and damaged valves, she was already on her way to the Mayo Clinic for open-heart surgery.\n\nSabine was one of roughly six to seven million Americans who took fenfluramine-based diet drugs during the 1990s, a wave of prescribing on a scale the country had rarely seen for a lifestyle drug. The eventual liability against the manufacturer would climb into the tens of billions of dollars before the lawsuits were finished. In September of 1997, the FDA asked manufacturers to pull the drugs from the market, but the prescriptions had already been written, and the damage, in many patients, had already been done.\n\n## A Country Ready for a Shortcut\n\nTo understand how a heart-damaging pill ended up in seven million American medicine cabinets, you have to start with the country that wanted it. By the early 1990s, obesity was being talked about in two contradictory registers at once, treated as a public health crisis on the evening news and as a personal failure in everyday conversation. That double pressure landed on real people who were trying to live their lives.\n\nDiet clinics were multiplying in strip malls from Florida to California, and the magazines at every grocery checkout sold transformation as the cover story of the month. Patients walked into doctors' offices exhausted, not just by their bodies but by years of stigma, by diets that collapsed, and by exercise plans that hadn't moved the scale. Many of them were not chasing a beach body but a simpler kind of relief from daily life.\n\nThey wanted to climb a flight of stairs without their knees burning, or to hear blood pressure numbers their doctors would stop frowning at. They wanted to stop being treated like a moral problem in waiting rooms and at family dinners. So when a new option started circulating through clinics, it arrived in front of people who had already tried, and failed, at almost everything else.\n\nDoctors began describing the combination in language that bordered on disbelief, calling it a near-miracle in interviews because it actually suppressed appetite in patients for whom nothing had worked. Word of mouth among physicians traveled faster than any formal guideline could, and patients started arriving at appointments asking for it by name. The conditions for mass uptake were already in place before anyone had a serious public conversation about long-term safety.\n\n## Two Old Pills Become One Promise\n\nHere's the thing about Fen-Phen that most people taking it didn't realize at the time. It wasn't a single new miracle drug invented in some breakthrough lab in the 1990s, and it had never been approved by the FDA as a combination product. It was two older pills that doctors had started prescribing together, with each pill carrying its own separate history and its own narrow approval.\n\nThe \"fen\" half was fenfluramine, sold under the brand name Pondimin, and the FDA had cleared it back in 1973 strictly for short-term obesity treatment. The \"phen\" half was phentermine, approved even earlier, also for short-term use, and it would later be excluded from the same valve-damage signal that brought the scandal down. On paper, both pills were tools for a brief intervention measured in weeks, not in months or years.\n\nThe mismatch sat right at the center of what would go wrong. Each drug had been studied and approved only for short courses, but Fen-Phen patients would end up taking the combination for months and sometimes years on end. Nothing in the original approval files anticipated that pattern of use, and nothing in the labeling required doctors to stop after a set period.\n\nThe combination got its public push from a researcher named Dr. Michael Weintraub, who started testing fenfluramine and phentermine together in patients during the 1980s. When his results were published, they reported average weight loss of around 32 pounds among patients who stayed on the combination through the study period. That number traveled through medical journals and then into the popular press, and it lodged itself in the minds of doctors who had spent careers watching obesity treatments disappoint everyone in the exam room.\n\nThe crucial wrinkle, the part that would matter later in courtrooms, was simple. The FDA had never approved fenfluramine and phentermine as a combination therapy, and it had certainly never approved either of them for the long-term, indefinite use that was about to sweep the country.\n\n## Off-label Becomes an Industry\n\nIn American medicine, there's a practice called off-label prescribing, and it's the hinge that this entire story turns on. Once the FDA approves a drug for any use, doctors are legally permitted to prescribe it for other conditions or in other ways based on their own clinical judgment. The practice is common, often reasonable, and it becomes dangerous when broad real-world use sprints ahead of the evidence supporting it.\n\nAfter Weintraub's findings were published in 1992, weight-loss clinics and primary care physicians increasingly wrote prescriptions for fenfluramine and phentermine together as a routine protocol. The combination spread by professional word of mouth, by clinic marketing, and by patients who had read about it and walked in asking. Within a few years, what had been a research curiosity was a standard menu item at diet clinics across the country.\n\nThis is where American Home Products enters the story, the pharmaceutical company that manufactured Pondimin and would later bring a related drug called Redux to market. By law, American Home Products could not advertise or market the combination, since the FDA had never approved Fen-Phen as a combo therapy. Sales of Pondimin nevertheless climbed sharply as the off-label pairing spread, and dedicated weight-loss clinics aggressively recruited patients into the protocol with newspaper ads and radio spots.\n\nSabine Sisk-Bisson's path into the drug was the ordinary one. She read about the combination, asked her doctor whether it might help with the fifteen pounds she wanted gone, and received the prescription through a normal office visit. There was no back alley, no shady supplier, and no warning sign that anyone in the exam room recognized as such.\n\n## The Chemistry Hits the Heart\n\nTo understand what those pills were doing inside Sabine's chest, you have to look at how each half of the combination actually worked. Fenfluramine, the \"fen\" in Fen-Phen, increased serotonin signaling in the brain, and that surge of serotonin was what helped patients feel full after smaller meals. Phentermine, the \"phen,\" worked along a different pathway, behaving more like a stimulant that blunted appetite by nudging the nervous system into a more alert state.\n\nOn paper, the two drugs were meant to balance each other out, with fenfluramine's sedating effect softened by phentermine's lift. In practice, the trouble lived inside the serotonin half of that equation, because serotonin signaling does not stay politely inside the brain's appetite center. The same chemical messengers that quieted hunger were also reaching tissues elsewhere in the body, including the delicate flaps of tissue that open and close inside the heart.\n\nHeart valves are simple in concept and unforgiving in failure, opening to let blood through and closing to keep it from sliding backward. When those valves thicken abnormally, they stop sealing the way they should, and blood begins to leak in the wrong direction with every beat. That backward leak forces the heart to work harder to push the same amount of blood forward, and over months and years, the muscle itself begins to suffer.\n\nThe Mayo Clinic team that later identified the cluster of damaged patients would help establish a link between fenfluramine-type drugs and exactly this pattern of valve injury. Patients showed up with valves that had grown stiff and irregular, leaking instead of closing cleanly, in a signature unusual enough that cardiologists noticed it across multiple cases. The damage did not announce itself with chest pain or sudden collapse, and many patients felt nothing wrong until the leakage was already significant.\n\nThere was a second, rarer danger riding along with the valve injury, and it carried its own grim name. Primary pulmonary hypertension is a condition in which the small blood vessels feeding the lungs become abnormally narrow, and pressure inside those vessels climbs to levels the right side of the heart was never designed to push against. It is progressive, often fatal, and historically very uncommon in the general population.\n\nThe framing line for everything that follows is simple enough to say out loud. Rare side effects do not stay rare when millions of people are taking the drug that causes them, because percentages turn into person counts very quickly at that kind of scale.\n\n## The Lung Warning Was Already There\n\nIn August of 1996, well before the Fen-Phen story became a national scandal, a hard scientific warning landed in one of the most respected medical journals in the world. *The New England Journal of Medicine* published a study by Lucien Abenhaim and colleagues examining the relationship between appetite suppressant drugs and primary pulmonary hypertension. Their finding was not subtle, and it was not buried in a footnote where readers could miss it.\n\nPatients who had used appetite suppressants such as fenfluramine for longer than three months carried roughly a twenty-three-fold higher risk of developing primary pulmonary hypertension compared with people who had never taken those drugs. A twenty-three-fold increase is not the kind of number that gets lost in statistical noise, and the journal it appeared in is read by physicians and regulators around the world. The warning was published, peer-reviewed, and available to anyone in the field who wanted to read it.\n\nThe warning also had a human face inside the American medical community. Dr. Stuart Rich, a pulmonary hypertension specialist, had been publicly raising concerns about this class of drugs and its association with the disease during the period when Redux was being considered for approval. He was not an obscure critic shouting from the margins, but a recognized expert in the exact condition the drugs appeared to cause.\n\nHere's the framing line again, because the next beat depends on it. Rare does not mean harmless when millions of patients are being exposed, since a low individual risk multiplied across a vast prescribing population produces a predictable and countable number of injured people. The warning existed in print. What the American medical system did in the months that followed is what makes the story unforgivable.\n\n## The Phen-frenzy Peaks\n\nThe publication of the *NEJM* warning did not slow the prescribing curve, and in some readings of the data it barely registered against the momentum already in motion. Through the second half of 1996, doctors across the country were reportedly writing tens of thousands of Fen-Phen prescriptions every week, with figures around eighty-five thousand prescriptions per week widely cited in later reporting. Sales of Pondimin and Redux together climbed to roughly three hundred million dollars in that single calendar year.\n\nThe numbers carry the point on their own, and they sit awkwardly next to the twenty-three-fold risk figure that had just been published in one of the country's most authoritative medical journals. A drug class with a documented and serious pulmonary signal was being dispensed at a pace of tens of thousands of prescriptions per week into a population that had not been warned at the point of sale. Estimates commonly place total American exposure during the 1990s at somewhere between six and seven million users across the various fenfluramine-based regimens.\n\nA therapy that had been approved for short-term use in narrow circumstances had become a mass-market lifestyle intervention, accumulating patients far faster than safety evidence was accumulating about long-term harm. Diet clinics advertised on local radio, primary care offices added the combination to their standard offerings, and patients asked for it by name. The system was running ahead of its own science, and nobody with the authority to slow it down was using that authority.\n\nNone of this happened because patients were reckless or vain, and the sharpness here belongs aimed at the institutions, not at the people who walked into clinics asking for help. Patients trusted the prescribers, the prescribers trusted the literature, and the literature was telling two different stories at the same time about whether the drugs were safe.\n\n## Redux Gets a Narrow Green Light\n\nTo understand how the prescribing curve kept climbing through 1996, you have to back up four months before the *NEJM* warning landed. In April of that year, the FDA approved dexfenfluramine, sold under the brand name Redux, a close chemical relative of fenfluramine designed for longer-term weight management. The approval was contested inside the agency in a way that the public would not fully learn about until years later.\n\nAccording to reporting by David Willman in the *Los Angeles Times*, the FDA advisory committee reviewing dexfenfluramine first voted five to three against approval, citing concerns about safety relative to the modest weight loss the drug produced. The committee was then reconvened, and on a second vote it narrowly recommended approval by a margin of six to five. The drug moved forward on the strength of that single-vote shift, against the backdrop of a first vote that had gone the other way.\n\nThe internal dissent did not stop at the advisory committee. FDA reviewer Dr. Leo Lutwak raised concerns about whether the drug's effectiveness justified its risk profile, and Dr. Solomon Sobel reportedly declined to sign the approval letter that cleared Redux for the American market. The specific worry that dissenters flagged inside the agency was the pulmonary hypertension signal already associated with the broader drug class, which was the precise harm the Abenhaim paper would crystallize four months later.\n\nThe regulators in the room were not cartoon villains, and the choice they faced was a genuine one. Obesity carries real and measurable harms across cardiovascular health, joint disease, and metabolic function, and the weight-loss tools available to physicians in 1996 were limited and largely disappointing. The agency was weighing those documented harms against drug risks that were still being characterized, and a narrow majority decided the benefits were worth the gamble. They got the balance wrong, and within eighteen months the same agency would be asking manufacturers to pull the drug off American shelves.\n\n## Mayo Finds the Valve Pattern\n\nThe break in the case did not arrive through a single dramatic discovery, and it did not arrive in Washington. It arrived in Rochester, Minnesota, where cardiologists at the Mayo Clinic were beginning to notice something they could not square with their usual caseload. Women in their thirties and forties were turning up with valve damage that looked nothing like the wear of aging hearts.\n\nDr. Heidi Connolly and her colleagues started comparing notes on these patients, looking for what they had in common beyond the unusual appearance of their echocardiograms. The shared thread was not a virus, not a family history, and not a previous surgery. The shared thread was a prescription, and the prescription was Fen-Phen.\n\nIn July of 1997, the Mayo team published its findings on twenty-four cases of unusual valvular heart disease in women who had taken the fenfluramine-phentermine combination. The pattern in the echocardiograms was distinctive enough that cardiologists reading the report could recognize it in their own waiting rooms. The signal had moved from anecdote to something a clinician could name out loud.\n\nThe FDA responded on July 8th with a public health advisory, asking physicians around the country to report similar cases through the agency's adverse event channels. Reports started arriving from cardiologists who had been quietly puzzled by their own patients, and the cluster widened from twenty-four cases to a count that kept climbing through the summer. An initial screening figure suggested that around thirty percent of exposed patients showed abnormal echocardiograms, a number that would later be substantially revised downward as more rigorous studies replaced the early criteria.\n\nThe exact prevalence took years to pin down, but the existence of the signal did not. Women who had walked into clinics asking to lose fifteen pounds were walking into cardiology offices being told their valves were leaking. The mechanism that the lab work had hinted at through the serotonin pathway was now visible on imaging in real patients across multiple states.\n\nBy late summer, the question inside the FDA was no longer whether the drugs were causing valve damage. The question was what to do about a medication that millions of Americans currently had on their kitchen counters.\n\n## The Withdrawal Patients Lived\n\nOn September 15th of 1997, the FDA announced that it had requested the voluntary withdrawal of fenfluramine and dexfenfluramine from the American market. The agency did not use the word ban, and the legal distinction would matter later, but the practical effect was that Pondimin and Redux were coming off pharmacy shelves. The manufacturers complied with the request within days.\n\nPhentermine, the other half of the combination, was not withdrawn, because the same valve-damage signal had not been shown for it in the Mayo data or the follow-up reporting. The drug that gave Fen-Phen the second half of its name remained legal, while the half carrying the serotonin mechanism was pulled.\n\nFor patients, the announcement landed without warning. Millions of people who had swallowed their prescribed dose on Tuesday were reading on Wednesday morning that the drug was being pulled and that they should consult their doctors about what to do next. The phone lines at primary care offices and diet clinics jammed within hours of the news breaking on television.\n\nSubsequent guidance from physicians and from the FDA urged former users to undergo cardiac evaluation, including echocardiograms that could detect valve damage even in patients who felt nothing wrong. The asymptomatic nature of the early injury was the reason the screening guidance went so wide, because waiting for symptoms meant waiting for damage that had already accumulated. Cardiology practices around the country began booking former Fen-Phen patients into echo appointments that stretched the calendar into the following year.\n\n## What the Numbers Meant at Home\n\nThe statistics in the FDA filings ran into the millions, and the human shape of those statistics looked like Rose Jonez. She told the *San Francisco Chronicle* that after taking Fen-Phen she had developed primary pulmonary hypertension, the rare and progressive lung condition that the Abenhaim paper had warned about the year before her exposure. Her injury was not valve damage but the other harm the drug class carried with it.\n\nBy the time she spoke publicly in September of 1997, she was living on supplemental oxygen and a medication pump that delivered her treatment continuously through a line in her chest. She was facing the possibility of a lung transplant, a surgery with its own steep risks and its own narrow odds of long-term survival. The fifteen or twenty pounds she had wanted to lose had been replaced by a disease that reshaped the boundaries of her day.\n\nRose Jonez sat on the pulmonary hypertension end of the harm spectrum, the rarer and more lethal of the two signature injuries linked to fenfluramine. Sabine Sisk-Bisson, from the Virginia case at the start of this story, sat on the valve-damage end of that same spectrum. Her open-heart surgery at the Mayo Clinic went forward as her cardiologists had planned, and she came through it.\n\nWhat she said afterward was that the experience had left her, in her own words, not the same person she had been before her diagnosis. The surgery had repaired the immediate mechanical problem inside her chest, and the recovery had carried its own long arc of fatigue and adjustment. She had walked into her doctor's office in 1996 asking for help with a fifteen-pound goal, and she had walked out of a hospital roughly two years later as a cardiac surgery patient.\n\nA third name worth marking here is Cynthia Cappel-Coffey, a Fen-Phen patient who developed primary pulmonary hypertension and did not survive it. Her case would become the center of a later courtroom fight measured in billions of dollars, and we will come back to her when the legal story takes over. For now her name sits in the column of patients for whom the drug's rarest harm proved fatal.\n\n## A Texas Jury Cracks the Door\n\nThe first courtroom verdict against the manufacturer arrived in August of 1999, in a Texas case brought by a plaintiff named Debbie Lovett. She had taken the Fen-Phen combination for roughly three and a half months beginning in October of 1995, and she later attributed her heart valve damage to that period of use. Her lawsuit named American Home Products, the manufacturer of Pondimin and Redux, as the defendant.\n\nHer lawyers argued that the company had minimized the cardiac warnings available to prescribing doctors and to patients during the years the drugs were on the market. American Home Products argued that her condition predated her exposure to the drug combination, and that obesity itself carried a greater long-term health risk than the medications used to treat it. The two sides put their experts in front of the jury and let twelve Texans decide which account they believed.\n\nThe jury came back with a verdict of twenty-three point three million dollars in favor of Debbie Lovett, a sum that included a punitive damages component on top of the compensatory award. The verdict figure represented what the jury announced in open court, not necessarily what the plaintiff ultimately received once post-trial motions and appeals worked through the system. Verdicts of that size routinely get reduced or settled at different numbers before the case is finally closed.\n\nWhat the Lovett verdict did, regardless of the final dollar figure, was establish that a jury was willing to hold American Home Products responsible for cardiac injury linked to its diet drugs. Plaintiffs' lawyers around the country had been waiting to see whether the first case to reach a verdict would land for the company or for the patient. The answer arrived in Texas, and the line of cases already filed behind Debbie Lovett began moving toward their own courtrooms.\n\n## The Settlement and What Came After\n\nThe Lovett verdict landed on American Home Products like a starter's pistol, because thousands of similar cases were already filed and waiting their turn. By October of 1999, the company had reached a proposed national settlement that the *Washington Post* reported at three point seven five billion dollars. The deal was designed to resolve a huge swath of Fen-Phen claims at once, rather than letting each case grind through a separate Texas-style trial.\n\nA federal judge gave the settlement final approval in August of 2000, and the payout structure was built in tiers based on how badly each patient had been hurt. People with no symptoms but documented exposure received medical monitoring and modest payments to cover follow-up cardiac screening. Patients with confirmed valve damage moved into a middle tier that paid out more, scaled to the severity of the leak and the treatment they had needed.\n\nAt the top of the tiered structure sat the patients with the most catastrophic injuries, the ones who had undergone heart surgery or developed pulmonary hypertension or died from the drug. Their families were eligible for substantially higher compensation, with the exact figure depending on medical records and a claims review process that stretched on for years. The settlement was meant to draw a line under the litigation, but a sizable group of plaintiffs chose to step outside it.\n\nThese plaintiffs opted out of the class deal and pursued their cases as individual lawsuits, betting that a jury might value their suffering at a number the settlement matrix would never reach. The most dramatic of those bets paid off in April of 2004, when a Texas jury awarded one billion dollars to the family of Cynthia Cappel-Coffey. She had died of pulmonary hypertension after taking fenfluramine, and her family had refused the class settlement to pursue the larger claim.\n\nWyeth, the company American Home Products had renamed itself, disputed the causation finding and said it had complied with FDA requirements at every stage. The company moved immediately to appeal the verdict, and Texas state law on punitive damages was expected to substantially reduce any final payment her family actually received. A billion-dollar headline in 2004 was not a billion dollars wired to a bank account, and the appeals process pulled the real number down.\n\nAcross the full arc of class settlement payments and opt-out litigation combined, Wyeth eventually set aside roughly twenty-one billion dollars to cover its Fen-Phen liabilities. That figure came from *Forbes* reporting in 2006 and stood as the most defensible round number for the total scale of the company's exposure. Money could pay medical bills and lost wages, and money could fund the ongoing cardiac monitoring that former patients still needed. Money could not put a damaged valve back the way it had been before the prescription was written.\n\n## What the Heart Remembered\n\nBy the time the litigation finally wound down, the twenty-one billion dollars in recorded Wyeth liabilities had grown into a sum that, by some accounting, exceeded the entire revenue Pondimin and Redux had generated during their years on the American market. The drugs had been profitable while they were being prescribed, and they became something else entirely once the cost of the harm was added to the ledger. The math ran in the wrong direction for the company that had brought them to patients.\n\nIn January of 2001, the Government Accountability Office published a report noting that most prescription drugs withdrawn from the American market in recent years had carried greater health risks for women than for men. Fen-Phen was not the only drug in that pattern, and the GAO framed the finding as a broader question about how safety signals were being detected and acted on across the regulatory system. Weight-loss drugs were heavily used by women, and the gendered pattern of harm fit that population directly.\n\nSomewhere in America right now, former Fen-Phen patients are still walking around with valves that were quietly altered by a prescription written in 1996. Some of them have been monitored by cardiologists every year or two since the withdrawal, with echocardiograms tracking whether the leak has stayed stable or worsened over time. Some of them stopped going to those appointments years ago, and some never received the screening guidance in the first place.\n\nSabine Sisk-Bisson had her surgery. Rose Jonez was on her oxygen pump and facing transplant when she spoke to the *San Francisco Chronicle*. Cynthia Cappel-Coffey did not live to see the verdict her family eventually won in a Texas courtroom.\n\nThe drug is gone from American pharmacies. What it did to those hearts is not.\n\n## Key Takeaways\n\n- Fen-Phen was an off-label combination of two older, short-term-approved drugs never cleared by the FDA for combined or long-term use.\n- Fenfluramine's serotonin mechanism caused silent, progressive heart valve damage and primary pulmonary hypertension in millions of users.\n- A 1996 New England Journal study warned of a 23-fold increased pulmonary hypertension risk, yet prescribing accelerated unabated.\n- The FDA narrowly approved Redux despite internal dissent, then requested withdrawal just 18 months later after Mayo Clinic identified the valve damage pattern.\n- Wyeth ultimately set aside roughly $21 billion for Fen-Phen liabilities, exceeding the drugs' total market revenue and leaving lasting patient harm.\n\n## Frequently Asked Questions\n\n### What was Fen-Phen and how did it work?\n\nFen-Phen was not a single drug but a combination of two older pills prescribed together: fenfluramine (brand name Pondimin, the 'fen' half) and phentermine (the 'phen' half). Fenfluramine increased serotonin signaling in the brain to help patients feel full after smaller meals, while phentermine worked as a stimulant that blunted appetite by nudging the nervous system into a more alert state. The two drugs were meant to balance each other, with fenfluramine's sedating effect softened by phentermine's lift.\n\n### Was Fen-Phen ever approved by the FDA as a combination therapy?\n\nNo. The FDA had never approved fenfluramine and phentermine as a combination therapy, and it had never approved either of them for long-term, indefinite use. Both drugs were individually approved only for short-term obesity treatment—fenfluramine in 1973 and phentermine even earlier. The combination spread through off-label prescribing after researcher Dr. Michael Weintraub published findings in the 1980s and 1992 showing average weight loss of around 32 pounds among patients who stayed on the combination.\n\n### What heart damage did Fen-Phen cause?\n\nFen-Phen caused two main types of harm. First, it damaged heart valves, causing them to thicken abnormally, stiffen, and leak instead of closing cleanly. This forced the heart to work harder and eventually caused the heart muscle to enlarge. Second, it caused primary pulmonary hypertension, a rare and often fatal condition where the small blood vessels feeding the lungs become abnormally narrow, creating pressure that the right side of the heart cannot withstand. The valve damage was linked to fenfluramine's serotonin mechanism, while phentermine was later excluded from the valve-damage signal.\n\n### How many Americans took fenfluramine-based diet drugs in the 1990s?\n\nRoughly six to seven million Americans took fenfluramine-based diet drugs during the 1990s. At the peak of prescribing in late 1996, doctors were reportedly writing about 85,000 Fen-Phen prescriptions per week. Sales of Pondimin and Redux together climbed to roughly $300 million in 1996 alone.\n\n### When was the warning about pulmonary hypertension published, and what did it find?\n\nIn August 1996, the New England Journal of Medicine published a study by Lucien Abenhaim and colleagues finding that patients who had used appetite suppressants such as fenfluramine for longer than three months carried roughly a twenty-three-fold higher risk of developing primary pulmonary hypertension compared with people who had never taken those drugs. Dr. Stuart Rich, a pulmonary hypertension specialist, had also been publicly raising concerns about this drug class during the same period.\n\n### How did the Mayo Clinic help expose the Fen-Phen heart valve problem?\n\nIn July 1997, Dr. Heidi Connolly and colleagues at the Mayo Clinic published findings on twenty-four cases of unusual valvular heart disease in women who had taken the fenfluramine-phentermine combination. These were women in their thirties and forties with valve damage that did not match aging hearts. The distinctive pattern in their echocardiograms allowed cardiologists to recognize the signal in their own patients. The FDA responded on July 8, 1997 with a public health advisory asking physicians to report similar cases.\n\n### When were fenfluramine and dexfenfluramine withdrawn from the market?\n\nOn September 15, 1997, the FDA announced it had requested the voluntary withdrawal of fenfluramine and dexfenfluramine from the American market. The manufacturers complied within days. Phentermine was not withdrawn because the valve-damage signal had not been shown for it. The FDA had approved dexfenfluramine (Redux) just sixteen months earlier, in April 1996, by a narrow 6-5 advisory committee vote after initially voting 5-3 against approval.\n\n### What was the total cost of Wyeth's Fen-Phen liabilities?\n\nWyeth (formerly American Home Products) eventually set aside roughly $21 billion to cover its Fen-Phen liabilities, according to Forbes reporting in 2006. This included a $3.75 billion national class settlement approved in August 2000, plus individual lawsuits including a $1 billion verdict (later reduced on appeal) for the family of Cynthia Cappel-Coffey, who died of pulmonary hypertension. The $21 billion figure exceeded the entire revenue Pondimin and Redux had generated during their years on the market.\n\n### What happened to Sabine Sisk-Bisson after taking Fen-Phen?\n\nSabine Sisk-Bisson, a Virginia woman who took Fen-Phen in spring 1996 to lose about fifteen pounds after quitting smoking, developed heart valve damage without initial symptoms. She later experienced exhaustion, became winded on small hills, and had difficulty completing long phone calls without stopping to breathe. Tests showed an enlarged heart and damaged valves, and she underwent open-heart surgery at the Mayo Clinic. She stated afterward that the experience left her 'not the same person she had been before her diagnosis.'\n\n### What did the Government Accountability Office report find about withdrawn prescription drugs?\n\nIn January 2001, the Government Accountability Office published a report noting that most prescription drugs withdrawn from the American market in recent years had carried greater health risks for women than for men. Fen-Phen was not the only drug in this pattern. The GAO framed this as a broader question about how safety signals were being detected and acted on across the regulatory system. Weight-loss drugs were heavily used by women, and the gendered pattern of harm fit that population directly.\n\n## Sources\n\n- [Original Into the Shadows video: Fen-Phen: The Weight Loss Drug that Destroys Your Heart](https://www.youtube.com/watch?v=nQAzH0Ck1jo)\n- [Hero image source](https://upload.wikimedia.org/wikipedia/commons/3/3b/Liberty_Natatorium_diving_tower_and_springboards%2C_Lynchburg%2C_Virginia%2C_2026-04-17.jpg) by Rosslieb / openverse, by-sa.\n\n## Related Coverage" url: https://intotheshadows.pub/article/fen-phen-weight-loss-drug-destroys-heart.md canonical: https://intotheshadows.pub/article/fen-phen-weight-loss-drug-destroys-heart datePublished: 2026-06-25 dateModified: 2026-06-25 author: - name: Simon Whistler url: https://intotheshadows.pub/author/simon-whistler publisher: Into the Shadows image: "https://media.intotheshadows.pub/cdn-cgi/image/width=1600,height=900,fit=cover,quality=80,format=auto/articles/nQAzH0Ck1jo/hero.jpg" type: Article contentHash: 25255b9798eae66befbb466da4d9b712b7419781ac98f03422d35cb8663b1398 tokens: 8915 summaryUrl: https://intotheshadows.pub/article/fen-phen-weight-loss-drug-destroys-heart.md.summary.md --- In the spring of 1996, a woman in Virginia named Sabine Sisk-Bisson decided she wanted to lose about fifteen pounds. She had just quit smoking, and the weight had crept on the way it does after people put down cigarettes. Her doctor wrote her a prescription for a diet drug combination that was everywhere that year, advertised in magazines and stocked in clinics across the country. The brand name on everyone's lips was Fen-Phen, and the early weeks did exactly what the marketing promised her. Her appetite quieted down, her clothes started fitting differently, and nothing about the routine felt reckless to anyone involved. It was legal, it was prescribed by a licensed physician, and she took it on the schedule she had been given. While the number on her scale was dropping, something else was happening inside her chest that no scale could measure. The valves of her heart were quietly thickening and beginning to leak, a process unfolding without symptoms she could feel. She didn't know yet, her doctor didn't know yet, and neither did the millions of other Americans swallowing the same combination that year. The exhaustion came first, the kind that doesn't match the day you've had. A small hill left her winded, and long phone calls became difficult to get through without stopping to breathe. By the time her tests came back showing an enlarged heart and damaged valves, she was already on her way to the Mayo Clinic for open-heart surgery. Sabine was one of roughly six to seven million Americans who took fenfluramine-based diet drugs during the 1990s, a wave of prescribing on a scale the country had rarely seen for a lifestyle drug. The eventual liability against the manufacturer would climb into the tens of billions of dollars before the lawsuits were finished. In September of 1997, the FDA asked manufacturers to pull the drugs from the market, but the prescriptions had already been written, and the damage, in many patients, had already been done. ## A Country Ready for a Shortcut To understand how a heart-damaging pill ended up in seven million American medicine cabinets, you have to start with the country that wanted it. By the early 1990s, obesity was being talked about in two contradictory registers at once, treated as a public health crisis on the evening news and as a personal failure in everyday conversation. That double pressure landed on real people who were trying to live their lives. Diet clinics were multiplying in strip malls from Florida to California, and the magazines at every grocery checkout sold transformation as the cover story of the month. Patients walked into doctors' offices exhausted, not just by their bodies but by years of stigma, by diets that collapsed, and by exercise plans that hadn't moved the scale. Many of them were not chasing a beach body but a simpler kind of relief from daily life. They wanted to climb a flight of stairs without their knees burning, or to hear blood pressure numbers their doctors would stop frowning at. They wanted to stop being treated like a moral problem in waiting rooms and at family dinners. So when a new option started circulating through clinics, it arrived in front of people who had already tried, and failed, at almost everything else. Doctors began describing the combination in language that bordered on disbelief, calling it a near-miracle in interviews because it actually suppressed appetite in patients for whom nothing had worked. Word of mouth among physicians traveled faster than any formal guideline could, and patients started arriving at appointments asking for it by name. The conditions for mass uptake were already in place before anyone had a serious public conversation about long-term safety. ## Two Old Pills Become One Promise Here's the thing about Fen-Phen that most people taking it didn't realize at the time. It wasn't a single new miracle drug invented in some breakthrough lab in the 1990s, and it had never been approved by the FDA as a combination product. It was two older pills that doctors had started prescribing together, with each pill carrying its own separate history and its own narrow approval. The "fen" half was fenfluramine, sold under the brand name Pondimin, and the FDA had cleared it back in 1973 strictly for short-term obesity treatment. The "phen" half was phentermine, approved even earlier, also for short-term use, and it would later be excluded from the same valve-damage signal that brought the scandal down. On paper, both pills were tools for a brief intervention measured in weeks, not in months or years. The mismatch sat right at the center of what would go wrong. Each drug had been studied and approved only for short courses, but Fen-Phen patients would end up taking the combination for months and sometimes years on end. Nothing in the original approval files anticipated that pattern of use, and nothing in the labeling required doctors to stop after a set period. The combination got its public push from a researcher named Dr. Michael Weintraub, who started testing fenfluramine and phentermine together in patients during the 1980s. When his results were published, they reported average weight loss of around 32 pounds among patients who stayed on the combination through the study period. That number traveled through medical journals and then into the popular press, and it lodged itself in the minds of doctors who had spent careers watching obesity treatments disappoint everyone in the exam room. The crucial wrinkle, the part that would matter later in courtrooms, was simple. The FDA had never approved fenfluramine and phentermine as a combination therapy, and it had certainly never approved either of them for the long-term, indefinite use that was about to sweep the country. ## Off-label Becomes an Industry In American medicine, there's a practice called off-label prescribing, and it's the hinge that this entire story turns on. Once the FDA approves a drug for any use, doctors are legally permitted to prescribe it for other conditions or in other ways based on their own clinical judgment. The practice is common, often reasonable, and it becomes dangerous when broad real-world use sprints ahead of the evidence supporting it. After Weintraub's findings were published in 1992, weight-loss clinics and primary care physicians increasingly wrote prescriptions for fenfluramine and phentermine together as a routine protocol. The combination spread by professional word of mouth, by clinic marketing, and by patients who had read about it and walked in asking. Within a few years, what had been a research curiosity was a standard menu item at diet clinics across the country. This is where American Home Products enters the story, the pharmaceutical company that manufactured Pondimin and would later bring a related drug called Redux to market. By law, American Home Products could not advertise or market the combination, since the FDA had never approved Fen-Phen as a combo therapy. Sales of Pondimin nevertheless climbed sharply as the off-label pairing spread, and dedicated weight-loss clinics aggressively recruited patients into the protocol with newspaper ads and radio spots. Sabine Sisk-Bisson's path into the drug was the ordinary one. She read about the combination, asked her doctor whether it might help with the fifteen pounds she wanted gone, and received the prescription through a normal office visit. There was no back alley, no shady supplier, and no warning sign that anyone in the exam room recognized as such. ## The Chemistry Hits the Heart To understand what those pills were doing inside Sabine's chest, you have to look at how each half of the combination actually worked. Fenfluramine, the "fen" in Fen-Phen, increased serotonin signaling in the brain, and that surge of serotonin was what helped patients feel full after smaller meals. Phentermine, the "phen," worked along a different pathway, behaving more like a stimulant that blunted appetite by nudging the nervous system into a more alert state. On paper, the two drugs were meant to balance each other out, with fenfluramine's sedating effect softened by phentermine's lift. In practice, the trouble lived inside the serotonin half of that equation, because serotonin signaling does not stay politely inside the brain's appetite center. The same chemical messengers that quieted hunger were also reaching tissues elsewhere in the body, including the delicate flaps of tissue that open and close inside the heart. Heart valves are simple in concept and unforgiving in failure, opening to let blood through and closing to keep it from sliding backward. When those valves thicken abnormally, they stop sealing the way they should, and blood begins to leak in the wrong direction with every beat. That backward leak forces the heart to work harder to push the same amount of blood forward, and over months and years, the muscle itself begins to suffer. The Mayo Clinic team that later identified the cluster of damaged patients would help establish a link between fenfluramine-type drugs and exactly this pattern of valve injury. Patients showed up with valves that had grown stiff and irregular, leaking instead of closing cleanly, in a signature unusual enough that cardiologists noticed it across multiple cases. The damage did not announce itself with chest pain or sudden collapse, and many patients felt nothing wrong until the leakage was already significant. There was a second, rarer danger riding along with the valve injury, and it carried its own grim name. Primary pulmonary hypertension is a condition in which the small blood vessels feeding the lungs become abnormally narrow, and pressure inside those vessels climbs to levels the right side of the heart was never designed to push against. It is progressive, often fatal, and historically very uncommon in the general population. The framing line for everything that follows is simple enough to say out loud. Rare side effects do not stay rare when millions of people are taking the drug that causes them, because percentages turn into person counts very quickly at that kind of scale. ## The Lung Warning Was Already There In August of 1996, well before the Fen-Phen story became a national scandal, a hard scientific warning landed in one of the most respected medical journals in the world. *The New England Journal of Medicine* published a study by Lucien Abenhaim and colleagues examining the relationship between appetite suppressant drugs and primary pulmonary hypertension. Their finding was not subtle, and it was not buried in a footnote where readers could miss it. Patients who had used appetite suppressants such as fenfluramine for longer than three months carried roughly a twenty-three-fold higher risk of developing primary pulmonary hypertension compared with people who had never taken those drugs. A twenty-three-fold increase is not the kind of number that gets lost in statistical noise, and the journal it appeared in is read by physicians and regulators around the world. The warning was published, peer-reviewed, and available to anyone in the field who wanted to read it. The warning also had a human face inside the American medical community. Dr. Stuart Rich, a pulmonary hypertension specialist, had been publicly raising concerns about this class of drugs and its association with the disease during the period when Redux was being considered for approval. He was not an obscure critic shouting from the margins, but a recognized expert in the exact condition the drugs appeared to cause. Here's the framing line again, because the next beat depends on it. Rare does not mean harmless when millions of patients are being exposed, since a low individual risk multiplied across a vast prescribing population produces a predictable and countable number of injured people. The warning existed in print. What the American medical system did in the months that followed is what makes the story unforgivable. ## The Phen-frenzy Peaks The publication of the *NEJM* warning did not slow the prescribing curve, and in some readings of the data it barely registered against the momentum already in motion. Through the second half of 1996, doctors across the country were reportedly writing tens of thousands of Fen-Phen prescriptions every week, with figures around eighty-five thousand prescriptions per week widely cited in later reporting. Sales of Pondimin and Redux together climbed to roughly three hundred million dollars in that single calendar year. The numbers carry the point on their own, and they sit awkwardly next to the twenty-three-fold risk figure that had just been published in one of the country's most authoritative medical journals. A drug class with a documented and serious pulmonary signal was being dispensed at a pace of tens of thousands of prescriptions per week into a population that had not been warned at the point of sale. Estimates commonly place total American exposure during the 1990s at somewhere between six and seven million users across the various fenfluramine-based regimens. A therapy that had been approved for short-term use in narrow circumstances had become a mass-market lifestyle intervention, accumulating patients far faster than safety evidence was accumulating about long-term harm. Diet clinics advertised on local radio, primary care offices added the combination to their standard offerings, and patients asked for it by name. The system was running ahead of its own science, and nobody with the authority to slow it down was using that authority. None of this happened because patients were reckless or vain, and the sharpness here belongs aimed at the institutions, not at the people who walked into clinics asking for help. Patients trusted the prescribers, the prescribers trusted the literature, and the literature was telling two different stories at the same time about whether the drugs were safe. ## Redux Gets a Narrow Green Light To understand how the prescribing curve kept climbing through 1996, you have to back up four months before the *NEJM* warning landed. In April of that year, the FDA approved dexfenfluramine, sold under the brand name Redux, a close chemical relative of fenfluramine designed for longer-term weight management. The approval was contested inside the agency in a way that the public would not fully learn about until years later. According to reporting by David Willman in the *Los Angeles Times*, the FDA advisory committee reviewing dexfenfluramine first voted five to three against approval, citing concerns about safety relative to the modest weight loss the drug produced. The committee was then reconvened, and on a second vote it narrowly recommended approval by a margin of six to five. The drug moved forward on the strength of that single-vote shift, against the backdrop of a first vote that had gone the other way. The internal dissent did not stop at the advisory committee. FDA reviewer Dr. Leo Lutwak raised concerns about whether the drug's effectiveness justified its risk profile, and Dr. Solomon Sobel reportedly declined to sign the approval letter that cleared Redux for the American market. The specific worry that dissenters flagged inside the agency was the pulmonary hypertension signal already associated with the broader drug class, which was the precise harm the Abenhaim paper would crystallize four months later. The regulators in the room were not cartoon villains, and the choice they faced was a genuine one. Obesity carries real and measurable harms across cardiovascular health, joint disease, and metabolic function, and the weight-loss tools available to physicians in 1996 were limited and largely disappointing. The agency was weighing those documented harms against drug risks that were still being characterized, and a narrow majority decided the benefits were worth the gamble. They got the balance wrong, and within eighteen months the same agency would be asking manufacturers to pull the drug off American shelves. ## Mayo Finds the Valve Pattern The break in the case did not arrive through a single dramatic discovery, and it did not arrive in Washington. It arrived in Rochester, Minnesota, where cardiologists at the Mayo Clinic were beginning to notice something they could not square with their usual caseload. Women in their thirties and forties were turning up with valve damage that looked nothing like the wear of aging hearts. Dr. Heidi Connolly and her colleagues started comparing notes on these patients, looking for what they had in common beyond the unusual appearance of their echocardiograms. The shared thread was not a virus, not a family history, and not a previous surgery. The shared thread was a prescription, and the prescription was Fen-Phen. In July of 1997, the Mayo team published its findings on twenty-four cases of unusual valvular heart disease in women who had taken the fenfluramine-phentermine combination. The pattern in the echocardiograms was distinctive enough that cardiologists reading the report could recognize it in their own waiting rooms. The signal had moved from anecdote to something a clinician could name out loud. The FDA responded on July 8th with a public health advisory, asking physicians around the country to report similar cases through the agency's adverse event channels. Reports started arriving from cardiologists who had been quietly puzzled by their own patients, and the cluster widened from twenty-four cases to a count that kept climbing through the summer. An initial screening figure suggested that around thirty percent of exposed patients showed abnormal echocardiograms, a number that would later be substantially revised downward as more rigorous studies replaced the early criteria. The exact prevalence took years to pin down, but the existence of the signal did not. Women who had walked into clinics asking to lose fifteen pounds were walking into cardiology offices being told their valves were leaking. The mechanism that the lab work had hinted at through the serotonin pathway was now visible on imaging in real patients across multiple states. By late summer, the question inside the FDA was no longer whether the drugs were causing valve damage. The question was what to do about a medication that millions of Americans currently had on their kitchen counters. ## The Withdrawal Patients Lived On September 15th of 1997, the FDA announced that it had requested the voluntary withdrawal of fenfluramine and dexfenfluramine from the American market. The agency did not use the word ban, and the legal distinction would matter later, but the practical effect was that Pondimin and Redux were coming off pharmacy shelves. The manufacturers complied with the request within days. Phentermine, the other half of the combination, was not withdrawn, because the same valve-damage signal had not been shown for it in the Mayo data or the follow-up reporting. The drug that gave Fen-Phen the second half of its name remained legal, while the half carrying the serotonin mechanism was pulled. For patients, the announcement landed without warning. Millions of people who had swallowed their prescribed dose on Tuesday were reading on Wednesday morning that the drug was being pulled and that they should consult their doctors about what to do next. The phone lines at primary care offices and diet clinics jammed within hours of the news breaking on television. Subsequent guidance from physicians and from the FDA urged former users to undergo cardiac evaluation, including echocardiograms that could detect valve damage even in patients who felt nothing wrong. The asymptomatic nature of the early injury was the reason the screening guidance went so wide, because waiting for symptoms meant waiting for damage that had already accumulated. Cardiology practices around the country began booking former Fen-Phen patients into echo appointments that stretched the calendar into the following year. ## What the Numbers Meant at Home The statistics in the FDA filings ran into the millions, and the human shape of those statistics looked like Rose Jonez. She told the *San Francisco Chronicle* that after taking Fen-Phen she had developed primary pulmonary hypertension, the rare and progressive lung condition that the Abenhaim paper had warned about the year before her exposure. Her injury was not valve damage but the other harm the drug class carried with it. By the time she spoke publicly in September of 1997, she was living on supplemental oxygen and a medication pump that delivered her treatment continuously through a line in her chest. She was facing the possibility of a lung transplant, a surgery with its own steep risks and its own narrow odds of long-term survival. The fifteen or twenty pounds she had wanted to lose had been replaced by a disease that reshaped the boundaries of her day. Rose Jonez sat on the pulmonary hypertension end of the harm spectrum, the rarer and more lethal of the two signature injuries linked to fenfluramine. Sabine Sisk-Bisson, from the Virginia case at the start of this story, sat on the valve-damage end of that same spectrum. Her open-heart surgery at the Mayo Clinic went forward as her cardiologists had planned, and she came through it. What she said afterward was that the experience had left her, in her own words, not the same person she had been before her diagnosis. The surgery had repaired the immediate mechanical problem inside her chest, and the recovery had carried its own long arc of fatigue and adjustment. She had walked into her doctor's office in 1996 asking for help with a fifteen-pound goal, and she had walked out of a hospital roughly two years later as a cardiac surgery patient. A third name worth marking here is Cynthia Cappel-Coffey, a Fen-Phen patient who developed primary pulmonary hypertension and did not survive it. Her case would become the center of a later courtroom fight measured in billions of dollars, and we will come back to her when the legal story takes over. For now her name sits in the column of patients for whom the drug's rarest harm proved fatal. ## A Texas Jury Cracks the Door The first courtroom verdict against the manufacturer arrived in August of 1999, in a Texas case brought by a plaintiff named Debbie Lovett. She had taken the Fen-Phen combination for roughly three and a half months beginning in October of 1995, and she later attributed her heart valve damage to that period of use. Her lawsuit named American Home Products, the manufacturer of Pondimin and Redux, as the defendant. Her lawyers argued that the company had minimized the cardiac warnings available to prescribing doctors and to patients during the years the drugs were on the market. American Home Products argued that her condition predated her exposure to the drug combination, and that obesity itself carried a greater long-term health risk than the medications used to treat it. The two sides put their experts in front of the jury and let twelve Texans decide which account they believed. The jury came back with a verdict of twenty-three point three million dollars in favor of Debbie Lovett, a sum that included a punitive damages component on top of the compensatory award. The verdict figure represented what the jury announced in open court, not necessarily what the plaintiff ultimately received once post-trial motions and appeals worked through the system. Verdicts of that size routinely get reduced or settled at different numbers before the case is finally closed. What the Lovett verdict did, regardless of the final dollar figure, was establish that a jury was willing to hold American Home Products responsible for cardiac injury linked to its diet drugs. Plaintiffs' lawyers around the country had been waiting to see whether the first case to reach a verdict would land for the company or for the patient. The answer arrived in Texas, and the line of cases already filed behind Debbie Lovett began moving toward their own courtrooms. ## The Settlement and What Came After The Lovett verdict landed on American Home Products like a starter's pistol, because thousands of similar cases were already filed and waiting their turn. By October of 1999, the company had reached a proposed national settlement that the *Washington Post* reported at three point seven five billion dollars. The deal was designed to resolve a huge swath of Fen-Phen claims at once, rather than letting each case grind through a separate Texas-style trial. A federal judge gave the settlement final approval in August of 2000, and the payout structure was built in tiers based on how badly each patient had been hurt. People with no symptoms but documented exposure received medical monitoring and modest payments to cover follow-up cardiac screening. Patients with confirmed valve damage moved into a middle tier that paid out more, scaled to the severity of the leak and the treatment they had needed. At the top of the tiered structure sat the patients with the most catastrophic injuries, the ones who had undergone heart surgery or developed pulmonary hypertension or died from the drug. Their families were eligible for substantially higher compensation, with the exact figure depending on medical records and a claims review process that stretched on for years. The settlement was meant to draw a line under the litigation, but a sizable group of plaintiffs chose to step outside it. These plaintiffs opted out of the class deal and pursued their cases as individual lawsuits, betting that a jury might value their suffering at a number the settlement matrix would never reach. The most dramatic of those bets paid off in April of 2004, when a Texas jury awarded one billion dollars to the family of Cynthia Cappel-Coffey. She had died of pulmonary hypertension after taking fenfluramine, and her family had refused the class settlement to pursue the larger claim. Wyeth, the company American Home Products had renamed itself, disputed the causation finding and said it had complied with FDA requirements at every stage. The company moved immediately to appeal the verdict, and Texas state law on punitive damages was expected to substantially reduce any final payment her family actually received. A billion-dollar headline in 2004 was not a billion dollars wired to a bank account, and the appeals process pulled the real number down. Across the full arc of class settlement payments and opt-out litigation combined, Wyeth eventually set aside roughly twenty-one billion dollars to cover its Fen-Phen liabilities. That figure came from *Forbes* reporting in 2006 and stood as the most defensible round number for the total scale of the company's exposure. Money could pay medical bills and lost wages, and money could fund the ongoing cardiac monitoring that former patients still needed. Money could not put a damaged valve back the way it had been before the prescription was written. ## What the Heart Remembered By the time the litigation finally wound down, the twenty-one billion dollars in recorded Wyeth liabilities had grown into a sum that, by some accounting, exceeded the entire revenue Pondimin and Redux had generated during their years on the American market. The drugs had been profitable while they were being prescribed, and they became something else entirely once the cost of the harm was added to the ledger. The math ran in the wrong direction for the company that had brought them to patients. In January of 2001, the Government Accountability Office published a report noting that most prescription drugs withdrawn from the American market in recent years had carried greater health risks for women than for men. Fen-Phen was not the only drug in that pattern, and the GAO framed the finding as a broader question about how safety signals were being detected and acted on across the regulatory system. Weight-loss drugs were heavily used by women, and the gendered pattern of harm fit that population directly. Somewhere in America right now, former Fen-Phen patients are still walking around with valves that were quietly altered by a prescription written in 1996. Some of them have been monitored by cardiologists every year or two since the withdrawal, with echocardiograms tracking whether the leak has stayed stable or worsened over time. Some of them stopped going to those appointments years ago, and some never received the screening guidance in the first place. Sabine Sisk-Bisson had her surgery. Rose Jonez was on her oxygen pump and facing transplant when she spoke to the *San Francisco Chronicle*. Cynthia Cappel-Coffey did not live to see the verdict her family eventually won in a Texas courtroom. The drug is gone from American pharmacies. What it did to those hearts is not. ## Key Takeaways - Fen-Phen was an off-label combination of two older, short-term-approved drugs never cleared by the FDA for combined or long-term use. - Fenfluramine's serotonin mechanism caused silent, progressive heart valve damage and primary pulmonary hypertension in millions of users. - A 1996 New England Journal study warned of a 23-fold increased pulmonary hypertension risk, yet prescribing accelerated unabated. - The FDA narrowly approved Redux despite internal dissent, then requested withdrawal just 18 months later after Mayo Clinic identified the valve damage pattern. - Wyeth ultimately set aside roughly $21 billion for Fen-Phen liabilities, exceeding the drugs' total market revenue and leaving lasting patient harm. ## Frequently Asked Questions ### What was Fen-Phen and how did it work? Fen-Phen was not a single drug but a combination of two older pills prescribed together: fenfluramine (brand name Pondimin, the 'fen' half) and phentermine (the 'phen' half). Fenfluramine increased serotonin signaling in the brain to help patients feel full after smaller meals, while phentermine worked as a stimulant that blunted appetite by nudging the nervous system into a more alert state. The two drugs were meant to balance each other, with fenfluramine's sedating effect softened by phentermine's lift. ### Was Fen-Phen ever approved by the FDA as a combination therapy? No. The FDA had never approved fenfluramine and phentermine as a combination therapy, and it had never approved either of them for long-term, indefinite use. Both drugs were individually approved only for short-term obesity treatment—fenfluramine in 1973 and phentermine even earlier. The combination spread through off-label prescribing after researcher Dr. Michael Weintraub published findings in the 1980s and 1992 showing average weight loss of around 32 pounds among patients who stayed on the combination. ### What heart damage did Fen-Phen cause? Fen-Phen caused two main types of harm. First, it damaged heart valves, causing them to thicken abnormally, stiffen, and leak instead of closing cleanly. This forced the heart to work harder and eventually caused the heart muscle to enlarge. Second, it caused primary pulmonary hypertension, a rare and often fatal condition where the small blood vessels feeding the lungs become abnormally narrow, creating pressure that the right side of the heart cannot withstand. The valve damage was linked to fenfluramine's serotonin mechanism, while phentermine was later excluded from the valve-damage signal. ### How many Americans took fenfluramine-based diet drugs in the 1990s? Roughly six to seven million Americans took fenfluramine-based diet drugs during the 1990s. At the peak of prescribing in late 1996, doctors were reportedly writing about 85,000 Fen-Phen prescriptions per week. Sales of Pondimin and Redux together climbed to roughly $300 million in 1996 alone. ### When was the warning about pulmonary hypertension published, and what did it find? In August 1996, the New England Journal of Medicine published a study by Lucien Abenhaim and colleagues finding that patients who had used appetite suppressants such as fenfluramine for longer than three months carried roughly a twenty-three-fold higher risk of developing primary pulmonary hypertension compared with people who had never taken those drugs. Dr. Stuart Rich, a pulmonary hypertension specialist, had also been publicly raising concerns about this drug class during the same period. ### How did the Mayo Clinic help expose the Fen-Phen heart valve problem? In July 1997, Dr. Heidi Connolly and colleagues at the Mayo Clinic published findings on twenty-four cases of unusual valvular heart disease in women who had taken the fenfluramine-phentermine combination. These were women in their thirties and forties with valve damage that did not match aging hearts. The distinctive pattern in their echocardiograms allowed cardiologists to recognize the signal in their own patients. The FDA responded on July 8, 1997 with a public health advisory asking physicians to report similar cases. ### When were fenfluramine and dexfenfluramine withdrawn from the market? On September 15, 1997, the FDA announced it had requested the voluntary withdrawal of fenfluramine and dexfenfluramine from the American market. The manufacturers complied within days. Phentermine was not withdrawn because the valve-damage signal had not been shown for it. The FDA had approved dexfenfluramine (Redux) just sixteen months earlier, in April 1996, by a narrow 6-5 advisory committee vote after initially voting 5-3 against approval. ### What was the total cost of Wyeth's Fen-Phen liabilities? Wyeth (formerly American Home Products) eventually set aside roughly $21 billion to cover its Fen-Phen liabilities, according to Forbes reporting in 2006. This included a $3.75 billion national class settlement approved in August 2000, plus individual lawsuits including a $1 billion verdict (later reduced on appeal) for the family of Cynthia Cappel-Coffey, who died of pulmonary hypertension. The $21 billion figure exceeded the entire revenue Pondimin and Redux had generated during their years on the market. ### What happened to Sabine Sisk-Bisson after taking Fen-Phen? Sabine Sisk-Bisson, a Virginia woman who took Fen-Phen in spring 1996 to lose about fifteen pounds after quitting smoking, developed heart valve damage without initial symptoms. She later experienced exhaustion, became winded on small hills, and had difficulty completing long phone calls without stopping to breathe. Tests showed an enlarged heart and damaged valves, and she underwent open-heart surgery at the Mayo Clinic. She stated afterward that the experience left her 'not the same person she had been before her diagnosis.' ### What did the Government Accountability Office report find about withdrawn prescription drugs? In January 2001, the Government Accountability Office published a report noting that most prescription drugs withdrawn from the American market in recent years had carried greater health risks for women than for men. Fen-Phen was not the only drug in this pattern. The GAO framed this as a broader question about how safety signals were being detected and acted on across the regulatory system. Weight-loss drugs were heavily used by women, and the gendered pattern of harm fit that population directly. ## Sources - [Original Into the Shadows video: Fen-Phen: The Weight Loss Drug that Destroys Your Heart](https://www.youtube.com/watch?v=nQAzH0Ck1jo) - [Hero image source](https://upload.wikimedia.org/wikipedia/commons/3/3b/Liberty_Natatorium_diving_tower_and_springboards%2C_Lynchburg%2C_Virginia%2C_2026-04-17.jpg) by Rosslieb / openverse, by-sa. ## Related Coverage